Articles related to CLINICAL TRIALS

A recent study highlights the efficacy of exagamglogene autotemcel, a CRISPR-Cas9 gene-edited therapy, in preventing severe vaso-occlusive crises in 97% of treated sickle cell disease patients over a 12-month period. This therapy not only promises reduced hospital visits but also sets a precedent in genetic treatments for hemoglobinopathies.

In the recent KEYNOTE-564 trial, adjuvant pembrolizumab therapy was shown to increase the 48-month overall survival rate to 91.2% compared to 86.0% with placebo among post-surgical patients with renal-cell carcinoma at increased risk of recurrence.

In this study, dostarlimab combined with carboplatin-paclitaxel demonstrated a marked improvement in progression-free and overall survival among endometrial cancer patients, particularly those with genetic markers for dMMR and MSI-H.

Reevaluating beta-blocker therapy post-myocardial infarction, a recent trial found no significant difference in the composite primary endpoint of death from any cause or new myocardial infarction between patients treated with long-term beta-blockers and those without.

In a recent phase 3 trial, alectinib has shown a notable improvement in both disease-free and CNS disease-free survival in patients with ALK-positive NSCLC, indicating a robust alternative to platinum-based chemotherapy regimens.

This study sheds light on lixisenatide’s potential in Parkinson’s disease, showing a notable slowing of motor disability progression, although accompanied by gastrointestinal side effects, underlining the importance of further research to validate these findings.